Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02699983
Other study ID # Pro20150001595
Secondary ID NCI-2015-02137Pr
Status Completed
Phase N/A
First received
Last updated
Start date January 8, 2016
Est. completion date July 29, 2018

Study information

Verified date April 2021
Source Rutgers, The State University of New Jersey
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized pilot clinical trial studies how well a virtual weight loss program (SparkPeople) works in helping female African American breast cancer survivors maintain a healthy weight. Many patients with breast cancer are overweight or gain weight after diagnosis. SparkPeople is a free web-based weight loss program that features educational and motivational articles and videos, self-monitoring tools, incentives, social support communities (including discussion forums, teams, challenges, and expert blogs), and options for content to be delivered to members' email. It is a comprehensive program that includes advice on diet, physical activity, and behavioral strategies (such as self-monitoring diet and exercise), and emphasizes safe weight loss and receiving medical attention regularly when needed. A web-based program such as SparkPeople may help breast cancer survivors maintain a healthy weight, which may reduce the risk of cancer returning and patient fatigue, and improve patient quality of life.


Description:

PRIMARY OBJECTIVES: I. Determine feasibility of using a free online commercial weight loss program (SparkPeople) in African-American (AA) breast cancer survivors, as measured by: 1) Accrual: percent (%) patients recruited and completing baseline assessments; 2) Study retention: % patients completing 6 month follow-up assessment; 3) Intervention adherence and sustainability (measured at 3, 6, 12 months): a) use of website- number of log-ins, time spent, and use of features such as food diaries, joining teams, posting on message boards (provided by SparkPeople); b) use of Fitbit monitor- % patients who wore the monitor and synced data; c) satisfaction (e.g., ease of use of website, usefulness of content, extra training and support needed) and barriers to participation (e.g., lack of computer access, lack of skills, time, interest, etc.). SECONDARY OBJECTIVES: I. Collect preliminary data on effect sizes of changes in our outcomes and potential mediators associated with the use of the online weight loss program. OUTLINE: Patients are randomized to 1 of 2 groups. All patients receive a handout of their personalized goals for weight loss, diet, and physical activity, with instructions to proceed slowly and as tolerated. Patients also wear a Fitbit monitoring device to monitor physical activity levels daily. GROUP I: Patients receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and may request additional training if needed. Patients are instructed to self-monitor their diet at least weekly using SparkPeople and physical activity levels daily using the Fitbit monitoring device, which integrates with the SparkPeople program. Patients receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Patients then enter the maintenance phase for an additional 3 months without reminders. GROUP II: Patients receive the weight loss handout and a Fitbit health monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date July 29, 2018
Est. primary completion date July 20, 2018
Accepts healthy volunteers No
Gender Female
Age group 21 Years to 75 Years
Eligibility Inclusion Criteria: - Patients must have evidence of histologically confirmed breast cancer, stage 0, I, II or III, and be at least 2 years post diagnosis - Patient is self-identified as African-American - Patient is overweight or obese (body mass index [BMI] >= 25 kg/m^2) - Patient is able to understand and read English - Patient must have home internet or smartphone access - Patient must give informed consent for this new study Exclusion Criteria: - Patient has a serious medical condition (e.g., stroke, liver or renal failure, congestive heart failure, myocardial infarction or cardiac surgery in past year, angina pectoris) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator - Patient has serious psychiatric condition (e.g., bipolar disorder, schizophrenia or other psychosis, bulimia or anorexia nervosa, suicide attempt within 6 months or current active suicidal ideation) that would compromise the patient's ability to complete the study, at the discretion of the investigator - Patient has severe disabilities limiting moderate physical activity, such as severe orthopedic conditions - Patient is planning major surgery within the next 6 months - Patient is taking medications or supplements for weight loss currently or within the past 3 months - Patient has successfully lost 5% of body weight in the previous 6 months or has had bariatric surgery - Patient is pregnant, breastfeeding, has given birth within the last 3 months or planning pregnancy within the next 12 months; if participant becomes pregnant during the course of the study, she will be removed from further participation - Patient is anticipating leaving the area within the next 12 months

Study Design


Intervention

Behavioral:
Behavioral Dietary Intervention
Use SparkPeople web-based program
Exercise Intervention
Use Fitbit monitor and SparkPeople web-based program
Device:
Activity Monitoring Device
Wear Fitbit activity monitoring device

Locations

Country Name City State
United States Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Rutgers, The State University of New Jersey National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment Rate Number of eligible participants who were enrolled and randomly assigned. Feasibility is defined as >= 75% recruitment rate. 12 months
Primary Retention Rate Number of participants completing study. Feasibility will be defined as >= 80% retention rate. 6 months
Primary Adherence to SparkPeople- Logged in average number of days logged per week in to SparkPeople website 0-3 months after intervention
Primary Adherence to SparkPeople- Logged in Average number of days per week logged in to SparkPeople website 4-6 months after intervention
Primary Adherence to SparkPeople- Logged Food Average number of days per week logged food into SparkPeople 0-3 months after intervention
Primary Adherence to SparkPeople- Logged Food Average number of days per week logged food into SparkPeople 4-6 months after intervention
Primary Acceptability of SparkPeople Usefulness of SparkPeople website on 1 (not useful at all) to 4 (very useful) scale 0-3 months after intervention
Primary Acceptability of SparkPeople Usefulness of SparkPeople website on 1 (not useful at all) to 4 (very useful) scale 4-6 months after intervention
Primary Adherence to Fitbit average days used Fitbit per week 0-3 months after intervention
Primary Adherence to Fitbit average days used Fitbit per week 4-6 months after intervention
Primary Acceptability of Fitbit Usefulness of Fitbit, rated on 1 (not useful at all) to 4 (very useful) scale 0-3 months after intervention
Primary Acceptability of Fitbit Usefulness of Fitbit, rated on 1 (not useful at all) to 4 (very useful) scale 4-6 months after intervention
Secondary Change in Weight Change in weight from baseline baseline and 3 months
Secondary Change in Weight Change in weight from baseline baseline and 6 months
Secondary Change in Waist Circumference Change in waist circumference from baseline baseline and 3 months
Secondary Change in Waist Circumference Change in waist circumference from baseline baseline and 6 months
Secondary Change in Caloric Intake Changes in caloric intake per day, measured by 24-hour recall baseline and 3 months
Secondary Change in Caloric Intake Changes in caloric intake per day, measured by 24-hour recall baseline and 6 months
Secondary Change in Physical Activity change in average number of steps per day measured using Fitbit monitor baseline and 3 months
Secondary Change in Physical Activity change in average number of steps per day measured using Fitbit monitor baseline and 6 months
Secondary Cardiopulmonary Fitness change in fitness, measured by the 6-minute walk test baseline and 3 months
Secondary Cardiopulmonary Fitness change in fitness, measured by the 6-minute walk test baseline and 6 months
Secondary Change in Quality of Life measured using Quality of Life in Adult Cancer Survivors Scale (minimum 65, maximum 257); higher scores mean worse quality of life baseline and 3 months
Secondary Change in Quality of Life measured using Quality of Life in Adult Cancer Survivors Scale (minimum 65, maximum 257); higher scores mean worse quality of life baseline and 6 months
Secondary Self-efficacy, Eating Healthy Foods change in self-efficacy, eating healthy foods, measured with Health Beliefs Survey, scale range 0 (certain I cannot) to 100 (certain I can) baseline and 3 months
Secondary Self-efficacy, Eating Healthy Foods change in self-efficacy, eating healthy foods, measured with Health Beliefs Survey, scale range 0 (certain I cannot) to 100 (certain I can) baseline and 6 months
Secondary Social Support for Healthy Nutrition change in social support for healthy nutrition, measured by Health Beliefs Survey, scale range 1 (strongly disagree) to 5 (strongly agree); a higher number, e.g., 5 (strongly agree) is the more favorable outcome baseline and 3 months
Secondary Social Support for Healthy Nutrition change in social support for healthy nutrition, measured by Health Beliefs Survey, scale range 1 (strongly disagree) to 5 (strongly agree); a higher number, e.g., 5 (strongly agree) is the more favorable outcome baseline and 6 months
See also
  Status Clinical Trial Phase
Completed NCT02235051 - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors N/A
Terminated NCT02454777 - High-Intensity Interval Training for Stage I-III Breast Cancer Patients N/A
Completed NCT03061175 - Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy N/A
Completed NCT01959490 - Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer Phase 2
Recruiting NCT03156309 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Terminated NCT01368263 - Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer Phase 2
Completed NCT01928186 - FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer N/A
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00070252 - Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT02780401 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Completed NCT02728596 - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) N/A
Completed NCT01478477 - Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole N/A
Completed NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Phase 1
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Completed NCT01672684 - Phase I: At-Home Support for Rural Women Using Group Video Calling Phase 1
Withdrawn NCT01695057 - Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer N/A
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01234532 - Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery Phase 2
Completed NCT00416715 - Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer Phase 2